Explore more publications!

The California STEM Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The California STEM Reporter.

Press releases published on December 10, 2025

Puro Sound Labs Launches the PuroGamer-BT: A Next-Generation Volume-Limiting Gaming Headset
SSOJet Launches Enterprise SSO Bridge for MCP, Enabling B2B SaaS Companies to Deploy AI-Ready Authentication in Days
IRVINEi to Debut OVAL - the World’s First AI Home Hub - at CES 2026
Beverly Hills Cosmetic Dentist Crafts JoJo Siwa’s $50K Smile Makeover
Artificio Launches Specialized AI Solutions for Insurance Claims, Legal Discovery, and Medical Records Processing
Hills Construction, Inc. Selects SocialSellinator to Accelerate Business Development with Strategic Google Ads Campaign
Rootstock Software Launches New Managed Services Offering
AqueoUS Vets® Partners with R2O Technologies to Continue Northeast Support
TechMatter Goes AI-First by Choosing Rinova AI and Raising the Bar for Medical Billing
Marketstrat Releases ‘World Market for Oncology Imaging AI 2023–2032,’ Mapping a US$604.7M Market to US$7.74B by 2032
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Selecting and Filtering in 3D CAD Assemblies: Faster Overview and Less Effort in the new Kisters 3DViewStation
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
MindPal.co Launches AI Recruiter Agent to Revolutionize Blue-Collar Hiring, Slashing Time-to-Hire and Operational Costs
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under  Nasdaq Listing Rule 5635(c)(4)
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Clearmind Medicine Announces 1-for-40 Reverse Share Split
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions